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The UK Science and Innovation Network UK-USA workshop ‘Beating the Superbugs: Hospital Microbiome Studies
for tackling Antimicrobial Resistance’ was held on October 14th 2013 at the UK Department of Health, London. The
workshop was designed to promote US-UK collaboration on hospital microbiome studies to add a new facet to our
collective understanding of antimicrobial resistance. The assembled researchers debated the importance of the
hospital microbial community in transmission of disease and as a reservoir for antimicrobial resistance genes,
and discussed methodologies, hypotheses, and priorities. A number of complementary approaches were explored,
although the importance of the built environment microbiome in disease transmission was not universally accepted.
Current whole genome epidemiological methods are being pioneered in the UK and the benefits of moving
to community analysis are not necessarily obvious to the pioneers; however, rapid progress in other areas of
microbiology suggest to some researchers that hospital microbiome studies will be exceptionally fruitful even
in the short term. Collaborative studies will recombine different strengths to tackle the international problems of
antimicrobial resistance and hospital and healthcare associated infections.
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Antimicrobial resistance (AMR) is a global challenge
and costs the NHS an estimated £1 billion a year, affect-
ing tens of thousands of lives [1]. UK leadership of the
G8 in 2013 led to a joint statement from the G8 science
ministers in June that identified AMR as a key priority* Correspondence: gilbertjack@uchicago.edu
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article, unless otherwise stated.[2]. A Department of Health/DEFRA 5 year strategy for
addressing AMR coincided with publication of the
Antibiotic Resistance Threat Report by the US Center
for Disease Control and Prevention [3]. These publica-
tions set out ways for both countries to steward existing
antibiotics and hasten the development of new anti-
microbial chemotherapies. Meanwhile, one of the most
important venues for transmission of antimicrobial
resistant pathogens is in healthcare settings. Approxi-
mately 5% of all patients admitted to a medical facilitytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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[4]. These infections cost an estimated 36–45 billion
dollars annually (2007 dollars [5]) and result in approxi-
mately 100,000 deaths [6].
Through the UK Research Councils, the Wellcome
Trust and National Institute for Health Research
(NIHR), the UK has invested heavily in transmission
studies of microbes that pose the biggest threat,
namely meticillin-resistant Staphylococcus aureus
(MRSA) and Clostridium difficile. These studies are
particularly prominent for their advanced use of
whole genome sequencing in the service of epidemi-
ology and infection control. The same advances in
sequencing technology which enable whole genome
epidemiology also enable the use of phylogenetically
open microbial community characterization and the
high-throughput molecular detection of antimicrobial
resistance genes, representing an orthogonal ap-
proach to hospital microbial ecology. The Hospital
Microbiome Project [7], led from the University of
Chicago, the Walter Reed Army Institute of Research
and the Uniformed Services University of the Health
Sciences, brings these technologies together in a
community ecology approach to the hospital, which
is less directly connected to individually diagnosed
infections and their control. This approach is a sig-
nificant departure from existing whole genome strat-
egies, which sensitively examine cultured clinical and
environmental isolates of bacteria or viruses that
present particular interest and generally threaten
nosocomial outbreaks. Microbiome studies provide
reduced characterization of individual strains while
embracing a wider phylogenetic diversity from each
sample.
Microbiome studies in hospitals seek to characterize
the health-promoting and disease-causing bacteria in
the hospital environment, to understand the conse-
quences of cleaning, ventilation, sterilization, and
prophylactic antibiotic use on the microbiome. The
community of organisms within the hospital is im-
portant for several reasons. First, genes conferring
antibiotic resistance reside in non-pathogenic organ-
isms in even the least-likely abiotic environments [8];
certainly this is also true within hospital environ-
ments. These genes can be transferred to pathogens,
thus resulting in new drug resistant, pathogenic or-
ganisms. Second, colonization resistance is the prop-
erty of most microbial communities; its mechanism is
slowly being better described [8,9] the colonization
resistance of the hospital microbiome – intact, dis-
turbed or engineered – may have a role in infection
control. Current hospital cleaning practices and anti-
biotic treatments do not consider the microbiome, but
concentrate on controlling target microorganisms.Perturbation or ablation of a hospital’s microbial ecol-
ogy through such interventions may therefore reduce
the competition experienced by pathogenic organisms
and result in their increased proliferations and capacity
to cause disease. Finally, the health promoting, or pro-
biotic effect of certain organisms and combinations of
organisms is well characterized in certain environ-
ments, such as the gut. Indeed, obesity has been shown
to correlate with particular variants of the gut micro-
biome [10,11]. The effect of the microbiome on the
health of a hospital building and its patients is cur-
rently unstudied and potentially significant.
The largest field component of the Hospital Micro-
biome Project (HMP) is designed to characterize the
taxonomic composition of surface-, air-, water-, and
human- associated microbial communities in the Uni-
versity of Chicago’s Center for Care and Discovery
(CCD) [12]. The 1st HMP Workshop (June 7th-8th
2012 [13];) explored the initial sampling strategy and
approach to building science measurements, and led to
the development of a full proposal to the Alfred P.
Sloan Foundation, and the creation of the Hospital
Microbiome Consortium [14]. The 2nd HMP Work-
shop (January 15th 2013 [15];) was held immediately
prior to the start of sampling in the CCD and was re-
sponsible for last minute changes to sample design and
sample handling, as well as numerous other facets of
the project implementation.
Here we present discussion and conclusions from
the UK Science and Innovation Network’s UK-USA
workshop ‘Beating the Superbugs: Hospital Micro-
biome Studies for tackling Antimicrobial Resistance’,
which was held on October 14th 2013 at the UK De-
partment of Health, London. This brought expertise
from the Hospital Microbiome Project in the US over
to the UK, via support from the UK Foreign and
Commonwealth Office, to interact with experts on
AMR, pathogen transmission, building science, public
health, etc. and to determine what UK research groups
could contribute to the built environment and human-
associated microbiome research? This was also an ex-
cellent opportunity to identify critical concerns and
valuable suggestions as to how the multiple research
arms associated with the eradication of nosocomial
infections could be better integrated. Finally, the
workshop agenda was laid out to facilitate maximum
discussion time regarding the value of microbiome
research in hospital environments. The meeting oc-
curred over one day, and the agenda consisted of 9
short presentations on the problem, the US experi-
ence, the UK research portfolio, and funding oppor-
tunities. This was followed by extensive discussion on
funding opportunities and the value of doing this re-
search in the UK, and extensive discussion on the
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research
Moderated by Jack Westwood (Head of Science and
Innovation, British Consulate-General, Chicago)
The UK Science and Innovation Network (SIN) together
with Public Health England and the Alfred P Sloan
Foundation (US) supported and convened a workshop in
London on 14th October to bring together Principal In-
vestigators from the HMP with 35 leading UK experts,
policy-makers and funding agencies to discuss the scope
for implementing microbiome studies in UK hospitals.
The first session included an introduction from Jack
Westwood who started off by thanking all for their at-
tendance and explaining why the UK SIN was interested
in promoting US-UK collaboration on hospital micro-
biology. He also highlighted the importance of public
engagement and active social networking, including the
twitter hashtag #hospitalmicro. Westwood described the
structure of the SIN, which includes 14 officers in the
USA, to actively promote UK scientific expertise in dif-
ferent geographical regions. The specific aims of the SIN
are to stimulate new scientific collaboration in strategic
areas, strengthen UK innovation, inform policymaking
and leadership, and influence science policy abroad.
Westwood represents the Midwest US, which currently
has ~ $7.4 Billion of US Federal research funding across
13 states [16], 79 million people, and represents a bigger
economy than Germany. Westwood highlighted that
AMR, and nosocomial infections generally, currently
costs the US economy ~ $20 million in direct, and $35
million in indirect healthcare costs. The UK strategy for
dealing with this problem highlights increased inter-
national collaboration.
Anthony Kessel (Director of Public Health Strategy at
PHE) then presented ‘Beating the Superbugs’ which
highlighted the interests and agenda of PHE. Kessel
reviewed key moments in the history of infection con-
trol, from the miasma to germ theory of disease, includ-
ing the roles of Antonie van Leeuwenhoek, Florence
Nightingale, Louis Pasteur, and Robert Koch, leading to
the 20th century revolution from transmission preven-
tion and chemical sterilization to specific antimicrobial
chemotherapy. In 1967 the US Surgeon General William
H. Stewart (Public Health Service) apocryphally an-
nounced that the war on infectious diseases was won
[17] despite the fact that Fleming had said as early as
1948 that microbial resistance to penicillin was inevit-
able. Kessel reminded us how rapidly things have chan-
ged, in that by 2011 a supposedly completely drug
resistant form of tuberculosis was found. Kessel identi-
fied the key limitations behind the fight against AMR,
including lack of novel antibiotics (only 1 new antibiotic
has been released on the market in the last 2 years), in-
appropriate use of antibiotics, and rapid evolution ofmulti-drug resistant bacteria. One of the last resort anti-
biotic against such organisms, meropenem, is currently
the 9th most used antibiotic in the UK. Kessel informed
the workshop that of the 7 priority areas for dealing with
AMR and nosocomial infections identified in the recent
Department of Health led UK cross-government AMR
strategy, 4 have been highlighted as being overseen
by PHE including: 1. Optimizing prescribing practice
(PHE-led; human health); 2. Improving infection pre-
vention and control (PHE-led; human health); 3. Raising
awareness and changing behavior (PHE-led; human
health); 4. Improving the evidence base through surveil-
lance (PHE-led; human health).
Jack Gilbert (University of Chicago, Argonne National
Laboratory, USA) led the introduction of the Alfred P
Sloan Foundation funded research program, the Hospital
Microbiome Project, which leverages DNA sequencing
of individual bacteria and bacterial/fungal communities
in hospital environments to discover reservoirs of AMR
and transmission routes for how bacteria move around
the hospital environment. The HMP is currently sam-
pling a private hospital, the Center for Care and Discov-
ery, at the University of Chicago, which was accessible
for ~5 weeks of sampling prior to any patients or med-
ical professionals using the building. The project has
been analyzing 10 patient rooms, 2 nursing stations and
the human incumbents of these spaces either daily or
weekly since Jan 15th 2013, and will finish this first
round of analysis on January 14th 2014. Initial results
have focused on exploring overlap between the micro-
bial communities in different spaces, associated with
different treatments for patient conditions, and have
shown significant differences, suggesting that different
patients and different treatment strategies leave specific
microbial signatures in a space. Gilbert demonstrated
the power of understanding the dynamics of the bac-
teria associated with different environments, especially
humans, and the impact on understanding disease pro-
gression and treatment outcomes (e.g. [18]).
Benjamin C. Kirkup (Walter Reed Army Institute for
Research, USA), co-PI of the HMP, discussed the com-
plementary arms of the project outside Chicago as well
as the larger need for hospital microbiome research. The
Department of Defense manages one of the world’s lar-
gest healthcare systems. The 232 Military Treatment
Facilities provide care to millions of patients, including
the combat wounded, active duty soldiers, dependants
and retirees. The military healthcare system takes an ac-
tive interest in the health and welfare of all patients, with
a special emphasis on those wounded in combat [19]
and deployed ‘disease and non-battle injury’ (DNBI
[20]). After the disclaimer, he led with a comment about
the partnership between the UK and US militaries and
their shared challenges as the result of asymmetric
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present serious sequelae of traumatic wounds from blasts
or large caliber weapons. The infections occur in a minority
of patients, but the measures to avoid infection impact all
patients; debridements and amputations must be more
conservative, tissue sparing less ambitious, and antibiotic
administration more aggressive. Wound contamination is
inevitable but epidemiology demonstrates that most infec-
tions derive from bacterial transmission within the health-
care environment. This is no fault of the providers; the
patients are severely compromised and complete isolation
is utterly impractical. At the same time, studies have dem-
onstrated that both traditional infection control measures
and hospital zoning can impact infection rates and charac-
ter [21]. The current methods of study are dependent on
culture methods [22,23] and are insufficient for effectively
characterizing the microbiome of wound infections in clin-
ical samples [24], the environmental microbiome in hos-
pital samples [25-27], or the asymptomatic carriage of
microbes by healthcare workers [28]. Because the art of
clinical microbiology does not seek to represent the entire
microbiome of the patient, but instead to select the patho-
gen like a needle from a haystack comparing molecular en-
vironmental surveys to culture-based patient assessments is
inappropriate. Similarly, comparing molecular diagnostics
in the patient to culture-based environmental surveillance
or carriage statistics would be inappropriate, and correla-
tions would be unlikely to generate meaningful results. The
strength of clinical microbiology is the long-established cor-
relations with clinical outcomes tailored in partnership with
existing practices and available chemotherapies. This ad-
vantage is slowly being eroded as molecular methods enter
the clinical laboratory and both associations and mecha-
nisms are established linking molecular diagnostics to clin-
ical outcomes [29,30]. One of the new outcomes from
molecular investigations is a better sense of the temporal
progression within healing and infected wounds. Systematic
progression, ecological succession even, has been demon-
strated in animal models [31] and potentially observed in
patients (Kirkup, unpublished data). This kind of progres-
sion suggests an extended opportunity for migration of bac-
teria both in and out of the wound over time and suggests
multiple opportunities for colonization and spread of both
pathogenic and healing compatible microbiomes. This ob-
servation motivates one arm of the Hospital Microbiome
Project, an effort to better understand the flow of organ-
isms from a patient into a single hospital room over time,
including the liminal spaces such as bandaging, clothing,
bedding and medical devices in contact with the patient.
An on-going study with samples from the Walter Reed Na-
tional Military Medical Center is characterizing related
samples in an observational fashion and bridging the gap
between culture and molecular methods in the hospital en-
vironment. Kirkup also emphasized that the existing studiesdo not do justice to the complexity of the problem; that
there is a need for further clinical studies, incorporating
epidemiology into hospital ecology, and for basic science,
both of which has been pioneered in the UK by researchers
addressing specific pathogens such as Clostridium difficile
and Staphylococcus aureus. He discussed specific needs for
a sub-sequence type understanding of bacterial ecology as
illustrated by antagonism diversity among closely related
organisms, and the need to investigate gene expression, fit-
ness and evolution in not only patient associated, but hos-
pital associated environments. Detailed evolution and
ecology in a hospital can only be fully resolved by experi-
mentation outside of a hospital; experiments are needed
with diverse bacteria, complex bacterial communities, and
simulacra of hospital environments at diverse scales and de-
grees of fidelity. His most ambitious suggestion was the de-
velopment of a national or international facility to house
experimental hospital rooms with independent HVAC and
plumbing; into which organisms could be introduced and
through which they could be tracked.
Mark Pallen (University of Warwick, UK) provided
insight into the long tradition of healthcare associ-
ated infection research in the UK, including John
Pringles pioneering work on disease progression in
hospitals in 1750; Florence Nightingale’s observations
that infection took away more life than bullets in
military conflict; and research by Gunn and Griffiths
into cross-infection within hospitals. Indeed, poten-
tially as a result of the pioneering and targeted ap-
proach that UK research has taken to tackle this
problem, the cases of meticillin-resistant Staphylococ-
cus aureus (MRSA) and Clostridium difficile in UK
hospitals has significantly declined in recent years.
Pallen highlighted the importance of the UKs na-
tional infrastructure, including the National Health
Service (NHS), PHE, and Genomics England, in pro-
viding multi-disciplinary interaction and facilitating
research. Indeed, research on microbial ecology and
ecosystem dynamics is also excellent in the UK,
which is essential if studies are to unpick the tangle
of interactions in hospital environments that may
lead to nosocomial infections. Pallen highlighted the
power of ‘joined-up-thinking’, by demonstrating how
the combination of experts in genomic epidemiology
hospital infection and control, and microbial ecology,
can be used to significantly improve patient outcomes
in hospital environments.
Four representatives of major UK funding agencies
and foundations then presented their portfolio of
research and funding programmes to the workshop.
Michael Ball from the Biotechnology and Biological
Sciences Research Council (BBSRC) discussed work
supported by metagenomic sequencing, as BBSRC do
not explicitly fund medical research (which is primarily
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showed research programs funded by BBSRC that sup-
port the development of tools, such as metagenomics
and bioinformatic analysis, which enable focus areas of
research in food security, bioenergy and the basic bio-
sciences underpinning health. The latter of these sup-
ports research providing evidence for health benefits in
humans and animals. This includes work on aging and
social activities that improve health, including work on
the microbiome. BBSRC also focuses on data rich sci-
ence, and synthetic biology. A recent BBSRC-funded
expert working group led to the development of a re-
sponsive mode call for proposals that would support
research that addresses resolving the technological and
methodological gaps in metagenomics. Additionally, a
network grant will shortly be awarded to build the
community, and will help to focus the research agenda
on improving metagenomic application and analysis.
Ghada Zoubiane (MRC) presented a summary on the
MRCs current portfolio on infection and bacteriology,
which supports ~ $500 million of research in this area,
including public health and infection control. Ghada ex-
plained that funding is through four Research Boards
(supporting project grants, programmes grants, centers
and partnership grants), MRC institutes and units, fel-
lowships and specific translational funding (Biomedical
Catalysts/DPFS and Confidence in Concept). The MRC
supported specific initiatives that are relevant to AMR.
This includes the MRC Centre for Molecular Bacteri-
ology and Infection (Imperial College London), the four
UKCRC Translational Infection Research Initiative con-
sortia, jointly funding and MRC-led, and two consortia
supported as part of the MRC-Canada partnership on
AMR. The MRC had major input into the Department
of Health five-year strategy on AMR and is currently ini-
tiating discussions with other research councils and
other major UK funders on future collaborations and co-
ordination of AMR related activities. MRC is the UK
representative at the European Joint Programming Ini-
tiative on AMR, which seeks to increase the value of na-
tional and EU research funding by joint planning,
implementation and evaluation of national research
programs.
Lara Bethke (The Wellcome Trust) introduced The
Wellcome Trust, a global charitable foundation dedi-
cated to achieving improvements in human and animal
health. The Wellcome Trust has an endowment of
around $27 billion USD and currently spends about $1.2
billion USD on charitable activities each year. The ma-
jority of their funding is either directly targeted to indi-
vidual researchers (fellowships or Investigator Awards) or
awarded for larger collaborative programmes (Strategic
Awards), although the Wellcome Trust also offers a var-
iety of other schemes that are tailored to particularfields or initiatives. They have historically supported
work in medical microbiology through their general
funding schemes. Most relevant to the Hospital Micro-
biome project, they have recently made three awards to
UK researchers involving genomic approaches to diag-
nostic and public health microbiology. These awards
were made through the Health Innovation Challenge
Fund, which is a parallel funding partnership between
the Wellcome Trust and the UK Department of Health
to stimulate the creation of innovative healthcare prod-
ucts, technologies, and interventions and to facilitate
their development.
Claire Kidgell (National Institute for Health Research)
introduced the NIHR, which was established in 2006 to
fund leading-edge NHS, social care and public health re-
search. Kidgell highlighted that the NIHR health re-
search system is comprised of four key components: i)
management and information systems; ii) infrastructure;
iii) faculty; iv) research programs. The NIHR specifically
funds applied research with the capacity to improve
patient and public health outcomes. In 2013, NIHR
issued a themed call for proposals is focused on AMR,
and was launched in direct response to the publication
of the 2nd volume of the 2011 Annual Report of the
Chief Medical Officer: Infections and the rise of anti-
microbial resistance with the goal of reducing the de-
velopment and spread of AMR [32]. Research in this
area may encompass better prevention and improved
surveillance.
Session 2: Discussion of potential UK funding and value
of the UK to such research
Moderated by Mark Pallen
Pallen led a lively discussion focused on the best way to
secure UK funding to tackle AMR, the potential to use
new technologies to explore the microbiome in health
care environments, and the value to the UK of such re-
search. A specific outcome of this discussion was that
the UK’s infrastructure of NHS trusts, combined with its
extensive and successful work in reducing the rate of
health care associated infections makes it an attractive
and productive option for implementing extensive stud-
ies of microbial ecology in hospitals. Mark Wilcox
pointed out that there is no point simply repeating
what’s already done in the US in a UK hospital; therefore
any experiments performed on the hospital microbiome
in the UK must be translational. Alison Holmes sug-
gested that the microbiome analysis in the existing net-
work of UK hospitals would provide opportunity for
working in many different clinical spaces, with networks
of staffing that can be manipulated to derive transla-
tional affects. Peter Wilson highlighted existing work on
tracking Clostridium difficile infections and spores on
surfaces in hospitals; this information is being used
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reservoirs of this specific organism. Julian Parkhill
highlighted the extensive research in UK hospitals on
near-real-time tracking of pathogen genomes in hospital
systems, and Derrick Crook has shown that most Clos-
tridium difficile cases originate from infections brought
into the hospital, not from internal reservoirs [24]. This
suggests that 16S rRNA amplicon and shotgun metage-
nomic tracking of microbial communities may not iden-
tify reservoirs for key nosocomial infections, and also
suggests that looking for reservoirs in the hospital might
not be an appropriate experimental approach. Beryl
Oppenheim pointed out that most of the existing re-
search and observational work has focused on symptom-
atic, not asymptomatic, patients, therefore we don’t
know the role of asymptomatic patients as conduits for
pathogen transfer, let alone the environment as a transient
reservoir. Jack Gilbert pointed out that if a non-pathogenic
strain passes through an asymptomatic patient, it might
become pathogenic following interactions with their
host microbiome or human-cells (e.g. [33-37]). There-
fore screening large numbers of patients and surfaces at
daily resolution may enable the identification of key
events of pathogenization of these organisms, which could
then be used to design specific validating experiments.
The discussion then moved on to what information
exists on staff carrying potentially pathogenic organisms,
and while frameworks for dealing with staff with MRSA,
Clostridium difficile, etc. do exist, we have no data on
whether staff sickness events (even for viruses, antibiotic
use, etc.) correlate with onset of nosocomial outbreaks.
Mark Wilcox suggested that staff could also be a reser-
voir, and importantly, while we often know about
classical pathogens and what their distribution is in a
given population, we know virtually nothing about
Gram-negative bacterial infections in these cohorts. In-
deed a lot of Gram-negative multidrug-resistant bacteria
are being identified, and these appear to be isolated in
specific sites in hospitals, e.g. Pseudomonas spp in neo-
natal wards [38]. There is an immediate need in any
population to move beyond the classification of the
major diseases, e.g. MRSA and Clostridium difficile, and
to expand into other nosocomial groups such as novel
Gram-negative strains, but also unknowns. Hence sur-
veys can play a role in uncovering new potential patho-
gens. Gilbert suggested that exploring the microbial
community could be very important for predicting
which people or buildings have the potential to become
infected or colonized by a given organism. Mark Wilcox
suggested that this was indeed the case, and the poten-
tial for susceptibility to be directed by the state of the
microbiome is absolutely biologically plausible, however,
the application of this at a scale relevant to hospital
patient turnover was not technically feasible. Wilcoxsuggested that longitudinal studies were essential to get
at these questions, and hence the existing Hospital
Microbiome Project had considerable potential. How-
ever, he pointed out that to get relevant information it is
essential to focus these longitudinal studies on high-
intensity spatial analysis, focused on a small site, com-
pared to spreading the research sampling too thinly.
Mark Pallen explored the translational potential of
microbiome analysis, e.g. even if we were able to identify
each disease in a system, how would we change hospital
architecture or operation to reduce infection rates, e.g. do
we isolate people? Develop specific strategies for patient
room rotations? Wilcox suggested the need to uncover
how to intervene in disease colonization and progression,
rather than ‘cleaning-up the mess’ afterwards. Therefore,
any efforts to characterize the microbial profiles associated
with nosocomial outbreak susceptibility/infection should be
designed to target mechanistic steps in infection that can
be interrupted. Pallen highlighted that this was key; i.e. why
do pathogens colonize certain people, and how do we stop
them from being infected? He suggested it might be pos-
sible to screen every patient coming into the hospital to
characterize their microbiome, pathogen load, and deter-
mine how they will respond to a given treatment. This may
also be used to drive zoning of patients within hospital
buildings, which could also influence building design.
Danny Wilson highlighted the power of genomics,
which has now been provided with an incredible breadth
of analysis; however, currently the application of metage-
nomics provides much less resolution than targeted
whole genome sequencing for detecting person-to-
person transmission. Gilbert disagreed about the degree
of resolution lost by an inability to assemble genomes.
He claimed that from metagenomics, one could deter-
mine which organism and functional types exist in a
space, and how the specific assemblage may interact
with known pathogens. Gilbert also suggested a correla-
tive function for metagenomic data; that the identifica-
tion of a metagenomic fingerprint with an absence of
outbreak activity would be indicative of a ‘healthy’ com-
munity that could be used to reduce risk of infection in
those people or spaces with a depleted microbiome, i.e. a
‘healthy probiotic’. Pallen highlighted that if we want to
use probiotics to improve health in buildings for people,
then we need to know that the bacteria we are adding
can never become pathogenic, however, this is a very
conservative approach and probably technically impos-
sible as bacteria can always evolve. Gilbert pointed out
that clinicians already use simple probiotics to augment
health in those that have taken antibiotics, and also to
reduce risk of infection from other pathogens.
From an architectural perspective, Peter Wilson
highlighted building materials as being key elements in
determining survival of microbes associated with a
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have a much higher transmissible potential, however,
this is currently poorly characterized. We know there
are high touch surfaces that are recognized transmis-
sion centers, and cleaning these has been shown to re-
duce the microbial density, but there is very little
information regarding whether this affects clinical
symptoms in patients. Phil Marsh suggested that different
cleaning strategies for different surface should be validated;
there is far too little data on how each cleaning strategy re-
duces infection risk. Jimmy Walker highlighted the need
for water surveillance especially for key pathogens such as
Legionella. Wilcox pointed out that there are extensive sur-
veillance projects out there, but they are not evenly distrib-
uted across different hospitals, or even within a given
hospital, which limits their effectiveness for interpretation.
Marsh suggested that funding for characterizing the
general health promoting aspects of bacteria, i.e. not
looking at disease causing organisms, was virtually im-
possible given the current funding climate. The MRC
and WT highlighted that their organizations welcome
research to promote health and wellbeing and are not
restricted to disease-focused projects.
In wrapping up this session, Gilbert suggested that while
it is no panacea, intense sampling and characterization of
the longitudinal and biogeographic distribution and dynam-
ics of the microbiota could help define predictive models,
especially when combined with infection control and im-
munity data, patient records, and building science measure-
ments. These models could be used to predict events in
other hospitals, which would then need to be validated.
Peter Wilson suggested that individual genomes couldn’t
be continuously surveilled, therefore the 16S rRNA ampli-
con sequencing could be used to target the environments
in which you might like to perform near-real-time genome
sequencing. Julian Parkhill asked a pertinent question, as to
whether big-data, i.e. massive characterization of a hospital
environment could actually help to predict disease out-
breaks and identify mechanisms of infection and transmis-
sion. Gilbert suggested it could, but that this would need to
be proven. Parkhill suggested that it would be essential then
to take a coordinated approach to analyzing the microbiota
in the built environment. However, determining which
disciplines to coordinate with would be the key to future
projects. Some examples given were, surgeons, clinical mi-
crobiologists, infection control and immunity, nurse teams,
cleaning staff, etc.
Session 4: Highlighting the potential issues for AMR and
microbiome research
Moderated by Dawn Field and Julian Parkhill
Session 3 tackled some aspects regarding the design of
microbiome experiments specifically to address poten-
tial translational elements into disease transmissioncharacterization in the hospital systems. The UK has
much to offer, and much to gain from such work. In-
tense discussion focused on existing differences in UK
and US methods for tackling AMR, especially regard-
ing experimental design. This also highlighted the dif-
ferences in scale and scope of project where the main
focus is to understand complex community dynamics
versus a single known pathogen (i.e. MRSA). Discus-
sions revealed that there is not yet a consensus on the
impact that the built environment microbiome has on
disease transmission in hospitals nor on the effect of differ-
ent types of surfaces. In fact it is possible that no such rela-
tionship exists. However, it is also possible that such a
scientific foundation may be required to help design future
experiments to test these hypotheses.
Parkhill started the discussion by highlighting that
there is the room to use genomic technologies to ex-
plore microbial community distribution, especially path-
ogens, in the built environment, and this is something
that could be extensively explored in the UK because of
its history of very detailed epidemiological, reductionist
focus on the spread of specific, major pathogens. How-
ever, there is extensive work that would need to be done
before it could be said to fulfill the specific translational
needs highlighted by the UK research councils. Much of
the clinical research agenda is driven by the need to im-
plement evidence-based approaches in clinical practice,
and stronger evidence of the value of microbiota studies
in this arena would be needed to convince the funding
agencies to follow this avenue of research.
Peter Hoffman brought up a significant concern with
microbial community profiling, specifically whether the
organisms identified are active or even transmissible,
i.e. just because a 16S rRNA sequence is present doesn’t
mean the corresponding bacterium is alive or infectious.
Also, in all these sampling efforts it is essential to distin-
guish between wet and dry environments; in dry envi-
ronments the microbes are probably not active and
could form contamination of a transient nature, but in
wet environments microbes are more than likely actively
interacting. Therefore, if the microbiome had the poten-
tial to influence pathogen dispersal or to determine
whether an organism could cause infection, it would
more than likely occur in the wet regions of a building.
Microbial contamination that lands in dry areas tends to
dry out too quickly for the microbes within it to repli-
cate, but Beryl Oppenheim suggested that just because
an organism has dried out on a surface, it does not mean
that it is dead – should the surface be re-wetted certain mi-
croorganisms might become replicate again. Peter Hoffman
also suggested it is very important that we define the terms
‘contamination’ and ‘colonization’; in contamination the or-
ganisms will not replicate and, once removed by cleaning,
will not re-establish; in colonization the organisms are
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for growth, and water is very important in this.
Parkhill suggested that correlative studies must always
be treated with care, for example, just because you have
Legionella in the water supply, and a Legionella outbreak
occurs in the hospital, it doesn’t necessarily mean that
these two facts are linked. To prove these instances
would require improved experimental design and reso-
lution of analysis. Microbiome analysis may not be able
to address this concern, but it is a powerful tool for sug-
gesting a relationship that could be tested.
Dawn Field encapsulated the 3 branches of analysis be-
ing discussed that could influence understanding of
AMR and nosocomial distribution through hospital en-
vironments. First, genome analysis of individual organ-
isms associated with disease events; second, population
dynamics of pathogens within the building and patient
population; finally, microbial ecology, which probably in-
fluences the previous avenues, and could help identify
novel pathogens, e.g. multidrug resistant Gram-negative
bacteria.
Wilcox suggested that instead of implementing “dis-
covery-focused” global microbiome analysis in the UK
hospital systems we should instead build on existing
strengths. For example, the UK has historically had more
success in controlling antimicrobial prescription and ap-
plication. In the US, due to the broader private health-
care system, and lack of a central doctrine, control of
antibiotic use is more problematic. For translation po-
tential, control of antibiotic application is probably the
most effective means to have rapid success. Field inter-
jected that this would require significant investigation of
the impact of human antibiotic use in medicine and the
food industry on environmental reservoirs, and their im-
pact on healthcare. However, it will not deal with all
nosocomial infections, and fails to uncover the mecha-
nisms associated with the development of new diseases.
Gilbert highlighted this by suggesting the potential of
metagenomics to identify and track the antibiotic resist-
ance of bacteria that we don’t normally track, e.g. non-
pathogens, which could have the potential to transfer
such resistance to pathogens.
Wilcox discussed how to design experiments, and
pointed out that it is currently impossible to do a statis-
tical power calculation to design specific experiments.
Derrick Crook suggested that this was a major issue with
microbiome research, in that observational strategies
could never be used effectively to answer these ques-
tions, just to pose more questions. Crook pointed out
that we don’t even know how to define disease state
properly within a patient, let alone how to correlate disease
state with changes in the microbiome of different patients,
and even further complications from the microbiome of
building spaces generates too many confounding factors tomake such data useful. This limited even the possibility to
define hypotheses from these data. However, the investiga-
tion space is vast, and these tools can help to contextualize
the spaces in which we can and cannot make such
progress.
Overall, the session revolved around the complications
of observational correlative analyses, and especially the
limitations. It was suggested that the funding climate
within the USA was more conducive to supporting the
exploration of whether the microbiome analysis tech-
niques could be used to make progress on the problem
of clinical AMR and nosocomial infections.
Session 4: Highlighting the potential issues for AMR and
microbiome research
Immediately prior to the wrap up and summary, Gilbert
chaired a session aimed at identifying potential focused
topics and areas of concern that must be dealt with
when considering AMR research, especially when exam-
ining the microbiome. Fourteen areas of interest were
identified by the workshop as being worthy of further
discussion, with the aim of developing these ideas in a
position paper.
(1). Public and professional engagement – the need to
have better communication between research
scientists and the public and clinical professionals
was identified as important. Explaining the key
problems associated with AMR research, and the
necessity for exploring novel analytical strategies
such as targeted microbiome research, is difficult,
and requires training to make any messages
effective.
(2). Pre-illness primary care analysis – a need for
understanding the ‘healthy’ microbiome of people
was identified as a key issue, not just as a test case
(e.g. NIH Human Microbiome Project), but in a
controlled clinical study to determine key
biomarkers associated with disease onset and/or
intra-hospital transmission events. Examining the
patient microbiome both before and after
hospitalization was suggested as important re-
search avenue.
(3). Global health strategy impacts – it was considered
highly important that any research performed
under these auspices be held up against a need to
impact global health strategies, i.e. not just those in
the USA and or UK. It would be very important
therefore to determine how microbiome studies
could be effectively explored in developing
countries.
(4). Assessing cleaning strategies in hospitals – it was
considered vitally important that more research be
focused on the value and impact of different
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important to explore inappropriate claims
regarding different strategies, and limit
expectations for novel ‘breakthroughs’. Cleaning
contains a major sociological factor that must be
considered, such as ‘pride in work’, and appropriate
pay, training and education for staff.
(5). Examining contribution of water versus air
contamination – the source and reservoirs of
nosocomial infections is particularly important.
Performing controlled experiments to examine the
relative contributions of the reservoirs in air and
water is essential; the majority of existing research
focuses on these separately, yet they directly and
indirectly interact.
(6). Antibiotic exposure – the culture of antibiotic use
must be far better catalogued (especially in the
USA) so that trends can be understood, and where
necessary, altered. This is essential to inform
genomic and metagenomic databases, so as to
define hospitals based on their antibiotic
administration culture. This may help identify new
ways in which we can alter treatment strategies
towards improved patient outcome.
(7). Impact of immune suppression on nosocomial
spread – to determine how these cohorts can
influence the spread and development of AMR and
nosocomial infections it is vital that these easy to
access cohorts are used for directed clinical trials.
Understanding whether their microbiota plays a
role in AMR and nosocomial spread will require
multidisciplinary research activities.
(8). Impact of illness frequency and disease state in
staff – difficulties with data acquisition due to fear
over job security, has led to limited information on
whether nosocomial infections or AMR has a
reservoir in staff. Most staff do not report in for
work when they are ill, however, records need to
be improved if we are to rule out this as a source.
(9). Gram-negative bacterial infections – one of the
understudied hospital infection types are those
bloodstream and critical care infections caused by
Gram-negative bacteria. The workshop identified
this as a vital area from improved research into
the ecology and transmission in health care
environments. For example, we know next to
nothing about their origin and mode of transmission,
especially when compared to ‘Clostridium difficile’
and MRSA.
(10). The impact of hospital ‘type’ on infection risk –
recent evidence has suggested that private health
care establishments in the UK have a higher level
of AMR than NHS facilities, and while this
evidence is circumstantial, it suggests that themanagement practices for infection control,
combined with the differences in patient
populations (e.g. more foreign national patients in
private healthcare), could have an impact on
nosocomial rates.
(11). Healthcare-associated architectural and
technological design – the need to consider the
influence of building and healthcare product
design on the development and spread of AMR
was specific highlighted. Particularly the need to
interact with and educate architects and product
designers, and co-develop experimental evidence
to support specific claims for key improvements.
(12). Development of metagenomic methodologies – as
highlighted by BBSRC, there is a vital need to
develop quantitative metagenomic tools to better
investigate microbial interactions that lead to the
development of AMR and pathogenicity. More
rigorous investigation of these tools, including
their limits, is needed to rely on them as a source
of valuable information.
(13). Understanding the impact of food and drink
provision in hospital environments – food and
drink, as well as general ‘alternative’ sources of
microbial contamination in hospitals need to be
more rigorously investigated. Many catering firms
for hospitals are regulated, but the aspects of
regulation that may lead to a reduction in the
development of AMR and nosocomial infections
associated with catering services is not fully
understood
(14). The role of selective decontamination – investigating
decontamination strategies that need to be
implemented when AMR pathogens are identified
need to be continuously re-evaluated, especially with
the potential of metagenomic methods to identify
novel bacteria, fungi and viruses, which could be a
cause of diseases for which a known trigger has not
yet been elucidated. Such novel taxa may have very
different responses to existing decontamination
methods.
While far from exhaustive, this list highlights a num-
ber of key areas that need to be considered, and for
which existing data is inadequate. As always, the re-
search community associated with this area is constantly
exploring new avenues, which exemplifies the need for
blue skies research paradigms.
Wrap-up and summary session
Consensus amongst the group was that microbiota are
likely to play a role in causing disease but there was
considerable debate over whether a greater understand-
ing of microbial communities in hospitals could provide
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origins, spread, and persistence of AMR, or could lead
to better targeted interventions. Extensive Twitter cover-
age with participants encouraged to tweet using the
hashtag #hospitalmicro generated a total of 82 original
tweets and 58 retweets with a total reach of 47,033
users, which highlights the reach of this meeting.
This was an interesting and worthwhile meeting that
may influence how AMR research is approached in the
UK. It was interesting to observe the divide between
existing US and UK approaches in this area, and the
skepticism of some of the UK representation on the im-
mediate value of conducting HMP-type studies in UK
hospitals. This was in part due to the more explicitly
translational agenda of UK funding agencies in the
clinical arena, compared to the willingness of US philan-
thropic foundations to generously support built environ-
ment microbiome studies, which when combined with
federal support from agencies such as the National
Institute for Health, currently stands at ~ $2.4bn. Implant-
ation of HMP studies in the UK has the potential to
be fruitful in increasing our understanding of hospital-
associated infections and could direct targeted intervention
strategies. However, in the current UK funding climate,
such studies would likely have to be more clearly transla-
tional to be successfully funded.Evening reception
An evening reception at the FCO included 35 additional
guests from government, industry, and the press, who
joined the workshop group to continue discussions, and
broaden interest in multiple AMR prevention strategies.
The group was joined by Prof John Watson (Department
of Health Deputy Chief Medical Officer), and Andrew
Jackson (Head of the UK Science and Innovation Net-
work and FCO Deputy Chief Scientific Advisor). Prof
Watson and Mr. Jackson addressed the group along with
Dr Gilbert, and emphasized the role of SIN in helping to
facilitate events such as these, the international aspects
of DH’s AMR strategy, and the outcomes of the work-
shops discussions. In general it was agreed that human
health and pathogens are a global issue, and countries
should be working together to develop a future in which
community level discovery and reductionist level patho-
gen genomics coordinate to create a knowledgebase to
help facilitate future work.
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